Insulin Resistance in Patients With Mood Disorder

Not Recruiting

Trial ID: NCT00242619


Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.

Official Title

Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study

Stanford Investigator(s)


Inclusion Criteria:- Current depression

   - Insulin resistance

   - Current physician/psychiatrist care

   - Between the ages of 18-60

   - Willing to sign the Human Subjects Protection Consent Form

   - Willing to have blood sampling Exclusion Criteria:- Diabetes

   - History of unstable heat disease

   - Uncontrolled hypertension

   - Extensive use of alcohol

   - Current use of street drugs

   - History of myocardial infarction

   - History of cerebrovascular disease


drug: rosiglitazone

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305